Laboratory Measurements of the Oral Direct Factor Xa Inhibitor Edoxaban Comparison of Prothrombin Time, Activated Partial Thromboplastin Time, and Thrombin Generation Assay

被引:50
作者
Morishima, Yoshiyuki [1 ]
Kamisato, Chikako [1 ]
机构
[1] Daiichi Sankyo, R&D Div, Biol Res Labs, Tokyo 1408710, Japan
关键词
Activated partial thromboplastin time; Coagulation assay; Direct factor Xa inhibitor; Monitoring; Prothrombin time; Thrombin generation assay; ATRIAL-FIBRILLATION; STROKE PREVENTION; IN-VITRO; WARFARIN; ANTICOAGULANTS; SAFETY; RIVAROXABAN;
D O I
10.1309/AJCPQ2NJD3PXFTUG
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Objectives: Edoxaban, an oral direct factor Xa inhibitor, does not require routine monitoring. However, assessment of the anticoagulant effects may be required in certain situations. Methods: We investigated the effects of edoxaban on prothrombin time (PT), activated partial thromboplastin time (aPTT), and thrombin generation using human platelet-poor plasma (PPP) or platelet-rich plasma (PRP). Results: Edoxaban concentration-dependently prolonged PT and aPTT. There was a considerable variation in the magnitude of PT prolongation among the reagents used The variability in aPTT prolongation among the reagents was smaller than that of PT Edoxaban concentration-dependently inhibited thrombin generation, with a more potent effect seen in PPP than in PRP. Thrombin generation assay was three times more sensitive to edoxaban than PT and aPTT. Conclusions: PT had disadvantages of a large variability among different PT reagents. aPTT could be used as a conventional and convenient test with a smaller variation among reagents. Thrombin generation was the most sensitive assay.
引用
收藏
页码:241 / 247
页数:7
相关论文
共 24 条
[1]  
[Anonymous], PATHOPHYSIOL HAEMOST
[2]   Clinical laboratory measurement of direct factor Xa inhibitors: Anti-Xa assay is preferable to prothrombin time assay [J].
Barrett, Yu Chen ;
Wang, Zhaoqing ;
Frost, Charles ;
Shenker, Andrew .
THROMBOSIS AND HAEMOSTASIS, 2010, 104 (06) :1263-1271
[3]   Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism [J].
Bueller, Harry R. ;
Decousus, Herve ;
Grosso, Michael A. ;
Mercuri, Michele ;
Middeldorp, Saskia ;
Prins, Martin H. ;
Raskob, Gary E. ;
Schellong, Sebastian M. ;
Schwocho, Lee ;
Segers, Annelise ;
Shi, Minggao ;
Verhamme, Peter ;
Wells, Phil .
NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (15) :1406-1415
[4]   Performance of coagulation tests in patients on therapeutic doses of rivaroxaban A cross-sectional pharmacodynamic study based on peak and trough plasma levels [J].
Francart, Suzanne J. ;
Hawes, Emily M. ;
Deal, Allison M. ;
Adcock, Dorothy M. ;
Gosselin, Robert ;
Jeanneret, Cheryl ;
Friedman, Kenneth D. ;
Moll, Stephan .
THROMBOSIS AND HAEMOSTASIS, 2014, 111 (06) :1133-1140
[5]   Edoxaban Versus Enoxaparin for the Prevention of Venous Thromboembolism: Pooled Analysis of Venous Thromboembolism and Bleeding From STARS E-3 and STARS J-V [J].
Fuji, Takeshi ;
Fujita, Satoru ;
Tachibana, Shintaro ;
Kawai, Yohko .
BLOOD, 2011, 118 (21) :97-97
[6]   Efficacy and Safety of Edoxaban Versus Enoxaparin for the Prevention of Venous Thromboembolism Following Total Hip Arthroplasty: STARS J-V. trial [J].
Fuji, Takeshi ;
Fujita, Satoru ;
Tachibana, Shintaro ;
Kawai, Yohko ;
Koretsune, Yukihiro ;
Yamashita, Takeshi ;
Nakamura, Mashio .
BLOOD, 2010, 116 (21) :1360-1360
[7]   DU-176b, a potent and orally active factor Xa inhibitor:: in vitro and in vivo pharmacological profiles [J].
Furugohri, T. ;
Isobe, K. ;
Honda, Y. ;
Kamisato-Matsumoto, C. ;
Sugiyama, N. ;
Nagahara, T. ;
Morishima, Y. ;
Shibano, T. .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2008, 6 (09) :1542-1549
[8]   Effect of the anti-factor Xa and anti-factor IIa activities of low-molecular-weight heparins upon the phases of thrombin generation [J].
Gerotziafas, G. T. ;
Petropoulou, A. D. ;
Verdy, E. ;
Samama, M. M. ;
Elalamy, I. .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2007, 5 (05) :955-962
[9]   Edoxaban versus Warfarin in Patients with Atrial Fibrillation [J].
Giugliano, Robert P. ;
Ruff, Christian T. ;
Braunwald, Eugene ;
Murphy, Sabina A. ;
Wiviott, Stephen D. ;
Halperin, Jonathan L. ;
Waldo, Albert L. ;
Ezekowitz, Michael D. ;
Weitz, Jeffrey I. ;
Spinar, Jindrich ;
Ruzyllo, Witold ;
Ruda, Mikhail ;
Koretsune, Yukihiro ;
Betcher, Joshua ;
Shi, Minggao ;
Grip, Laura T. ;
Patel, Shirali P. ;
Patel, Indravadan ;
Hanyok, James J. ;
Mercuri, Michele ;
Vogelmann, O. ;
Gonzalez, C. ;
Ahuad Guerrero, R. ;
Rodriguez, M. ;
Albisu, J. ;
Rosales, E. ;
Allall, O. ;
Reguero, M. ;
Alvarez, C. ;
Garcia, M. ;
Ameriso, S. ;
Ameriso, P. ;
Amuchastegui, M. ;
Caceres, M. ;
Beloscar, J. ;
Petrucci, J. ;
Berli, M. ;
Budassi, N. ;
Valle, M. ;
Bustamante Labarta, G. ;
Saravia, M. ;
Caccavo, A. ;
Fracaro, V. ;
Cartasegna, L. ;
Novas, V. ;
Caruso, O. ;
Saa Zarandon, R. ;
Colombo, H. ;
Morandini, M. ;
Cuello, J. .
NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (22) :2093-2104
[10]   Assessment of apixaban plasma levels by laboratory tests: suitability of three anti-Xa assays [J].
Gouin-Thibault, Isabelle ;
Flaujac, Claire ;
Delavenne, Xavier ;
Quenet, Sara ;
Horellou, Marie-Helene ;
Laporte, Silvy ;
Siguret, Virginie ;
Lecompte, Thomas .
THROMBOSIS AND HAEMOSTASIS, 2014, 111 (02) :240-248